Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial
| Autor: | Andreas Baumbach, Ravindra Kumar, Steffen Helqvist, Pieter C. Smits, Luc Wasungu, Yoshinobu Onuma, Manel Sabaté, Jan J. Piek, Patrick W. Serruys, Ad J. van Boven, Bernard Chevalier |
|---|---|
| Přispěvatelé: | Cardiology, Amsterdam Cardiovascular Sciences |
| Rok vydání: | 2016 |
| Předmět: |
Target lesion
Male medicine.medical_specialty medicine.medical_treatment Myocardial Infarction Myocardial Ischemia Antineoplastic Agents Coronary Artery Disease 030204 cardiovascular system & hematology law.invention 03 medical and health sciences 0302 clinical medicine Percutaneous Coronary Intervention Postoperative Complications Randomized controlled trial law Absorbable Implants Myocardial Revascularization Medicine Humans Single-Blind Method 030212 general & internal medicine Everolimus Aged Aspirin Tissue Scaffolds business.industry Graft Occlusion Vascular Percutaneous coronary intervention Stent Drug-Eluting Stents Thrombosis Middle Aged medicine.disease Surgery Treatment Outcome Cardiovascular Diseases Female Cardiology and Cardiovascular Medicine business Mace medicine.drug |
| Zdroj: | EuroIntervention, 12(9), 1102-1107. EuroPCR |
| ISSN: | 1969-6213 1774-024X |
| Popis: | Aims The one-year randomised data of the ABSORB II trial showed that the everolimus-eluting bioresorbable scaffold and the everolimus-eluting metallic stent were comparable for the composite secondary clinical outcomes of patient-oriented composite endpoint (PoCE) and device-oriented composite endpoint (DoCE)/target lesion failure (TLF), MACE and TVF. This report describes the two-year clinical outcomes of the ABSORB II trial. Methods and results Patients were randomly assigned in a 2:1 ratio to receive treatment with an everolimus-eluting bioresorbable scaffold (Absorb; Abbott Vascular, Santa Clara, CA, USA) or treatment with an everolimus-eluting metallic stent (XIENCE; Abbott Vascular). The trial enrolled 501 patients. Clinical follow-up at two years was available in 320 patients in the Absorb BVS arm and 160 patients in the XIENCE arm. At two years, the PoCE for the Absorb and XIENCE arms was 11.6% and 12.8% (p=0.70) and the DoCE/TLF was 7.0% and 3.0% (p=0.07), respectively. The hierarchical ID-MACE rate was 7.6% vs. 4.3% (p=0.16) and the rate of TVF was 8.5% vs. 6.7% (p=0.48). The definite/probable thrombosis rate was 1.5% in the Absorb arm vs. 0% in the XIENCE arm (p=0.17). Thirty-six percent and 34% of patients remained on DAPT at two years, respectively. Ninety-two percent of patients in both arms remained on aspirin. Conclusions Two-year clinical results demonstrate sustained low rates of PoCE, MACE, DoCE and TVF with the Absorb BVS as compared to the XIENCE stent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|